Furthermore, considering the importance of PNPLA3 polymorphisms in the etiology of NAFLD and, more crucially, HCC, genetic testing of particular groups, such as individuals with NAFLD but no metabolic syndrome symptoms, may be prudent [45]. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.